Literature DB >> 33846376

Low expression of the PPARγ-regulated gene thioredoxin-interacting protein accompanies human melanoma progression and promotes experimental lung metastases.

Patrick Meylan1, Christine Pich1,2, Carine Winkler1, Stefanie Ginster1, Lionel Mury1, Marie Sgandurra1,3, René Dreos1, Dennie Tompers Frederick4, Marc Hammond4, Genevieve Marie Boland4, Liliane Michalik5.   

Abstract

The thioredoxin system plays key roles in regulating cancer cell malignancy. Here we identify the Thioredoxin-interacting protein (TXNIP) as a gene, which expression is regulated by PPARγ in melanoma cells. We show that high TXNIP expression levels associate with benign melanocytic lesions, with tumor regression in patients on MAP kinase targeted therapy, with decreased proliferation in patients' melanoma biopsies, and with cell cycle arrest in human melanoma cell lines. In contrast, reduced TXNIP expression associates with advanced melanoma and with disease progression in patients. TXNIP depletion in human melanoma cells altered the expression of integrin beta-3 and the localization of the integrin alpha-v/beta-3 dimer at their surface. Moreover, TXNIP depletion affected human melanoma cell motility and improved their capacity to colonize mouse lungs in an in vivo assay. This study establishes TXNIP as a PPARγ-regulated gene in melanoma cells, thereby suggesting a link between these two proteins both involved in the regulation of cancer and of energy metabolism. It also reveals that the decrease in TXNIP expression, which is observed in advanced patient tumors, likely favors lung metastatic seeding of malignant cells.

Entities:  

Year:  2021        PMID: 33846376     DOI: 10.1038/s41598-021-86329-5

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  27 in total

Review 1.  Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance.

Authors:  Samuel Lee; Soo Min Kim; Richard T Lee
Journal:  Antioxid Redox Signal       Date:  2012-06-26       Impact factor: 8.401

Review 2.  The role of thioredoxin system in cancer: strategy for cancer therapy.

Authors:  Jin-Jing Jia; Wen-Shuo Geng; Zhan-Qi Wang; Lei Chen; Xian-Si Zeng
Journal:  Cancer Chemother Pharmacol       Date:  2019-05-11       Impact factor: 3.333

Review 3.  Diabetes pathogenic mechanisms and potential new therapies based upon a novel target called TXNIP.

Authors:  Lance Thielen; Anath Shalev
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2018-04       Impact factor: 3.243

Review 4.  Gaining momentum: New options and opportunities for the treatment of advanced melanoma.

Authors:  Olivier Michielin; Christoph Hoeller
Journal:  Cancer Treat Rev       Date:  2015-06-04       Impact factor: 12.111

Review 5.  Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the 'future' in dermatology therapeutics?

Authors:  Mrinal Gupta; Vikram K Mahajan; Karaninder S Mehta; Pushpinder S Chauhan; Ritu Rawat
Journal:  Arch Dermatol Res       Date:  2015-05-19       Impact factor: 3.017

Review 6.  Thiazolidinediones and PPARγ agonists: time for a reassessment.

Authors:  Bertrand Cariou; Bernard Charbonnel; Bart Staels
Journal:  Trends Endocrinol Metab       Date:  2012-04-17       Impact factor: 12.015

7.  Induction of Paracrine Signaling in Metastatic Melanoma Cells by PPARγ Agonist Rosiglitazone Activates Stromal Cells and Enhances Tumor Growth.

Authors:  Christine Pich; Patrick Meylan; Beatris Mastelic-Gavillet; Thanh Nhan Nguyen; Romain Loyon; Bao Khanh Trang; Hélène Moser; Catherine Moret; Christine Goepfert; Jürg Hafner; Mitchell P Levesque; Pedro Romero; Camilla Jandus; Liliane Michalik
Journal:  Cancer Res       Date:  2018-09-05       Impact factor: 12.701

8.  Editor's Highlight: PPARβ/δ and PPARγ Inhibit Melanoma Tumorigenicity by Modulating Inflammation and Apoptosis.

Authors:  Michael G Borland; Pei-Li Yao; Ellen M Kehres; Christina Lee; Amanda M Pritzlaff; Elizabeth Ola; Ashley L Wagner; Brooke E Shannon; Prajakta P Albrecht; Bokai Zhu; Boo-Hyon Kang; Gavin P Robertson; Frank J Gonzalez; Jeffrey M Peters
Journal:  Toxicol Sci       Date:  2017-10-01       Impact factor: 4.849

Review 9.  Thioredoxin/Txnip: redoxisome, as a redox switch for the pathogenesis of diseases.

Authors:  Eiji Yoshihara; So Masaki; Yoshiyuki Matsuo; Zhe Chen; Hai Tian; Junji Yodoi
Journal:  Front Immunol       Date:  2014-01-09       Impact factor: 7.561

10.  The Janus face of rosiglitazone.

Authors:  Christine Pich; Liliane Michalik
Journal:  Oncotarget       Date:  2018-12-28
View more
  3 in total

Review 1.  PPARs and Tumor Microenvironment: The Emerging Roles of the Metabolic Master Regulators in Tumor Stromal-Epithelial Crosstalk and Carcinogenesis.

Authors:  Hong Sheng Cheng; Yun Sheng Yip; Eldeen Kai Yi Lim; Walter Wahli; Nguan Soon Tan
Journal:  Cancers (Basel)       Date:  2021-04-29       Impact factor: 6.639

Review 2.  Potential Therapeutic Effects of PPAR Ligands in Glioblastoma.

Authors:  Rossella Basilotta; Marika Lanza; Giovanna Casili; Giulia Chisari; Stefania Munao; Lorenzo Colarossi; Laura Cucinotta; Michela Campolo; Emanuela Esposito; Irene Paterniti
Journal:  Cells       Date:  2022-02-10       Impact factor: 6.600

Review 3.  NRF2 and Key Transcriptional Targets in Melanoma Redox Manipulation.

Authors:  Evan L Carpenter; Alyssa L Becker; Arup K Indra
Journal:  Cancers (Basel)       Date:  2022-03-16       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.